MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Primo Lara
University of California, Davis
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tower Cancer Research Foundation
Beverly Hills, California, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- City of Hope South Pasadena
South Pasadena, California, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2011
- Primary completion
- 31 Aug 2015
- Completion
- 31 Aug 2015
- Last update posted
- 29 Nov 2016
- Registered enrollment
- 80
- Registry id
- NCT01294306
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.